Trend of A-share and Hong Kong stock innovative drug sector this week
In the second week of March 2022, a total of 5 stocks in the innovative drug sector in mainland and Hong Kong rose and 47 stocks fell. Among them, the top three gainers are Frontier Biotechnologies Inc(688221) -u (+ 13.6%), Shanghai Junshi Biosciences Co.Ltd(688180) -u (+ 6.62%), and gakos-b (+ 5.17%). The top three declines were Keji pharmaceutical-b (- 25.84%), Hehuang Pharmaceutical (- 25.07%) and Geli pharmaceutical-b (- 21.52%). This week, the A-share innovative drug sector fell 5.27%, underperforming the CSI 300 index by 4.22pp, and biomedicine fell 2.62%. In the past six months, A-share innovative drugs have fallen by 13.75%, underperforming the Shanghai and Shenzhen 300 index by 10.74pp, and biomedicine has fallen by 26.3%. This week, the innovative medicine sector of Hong Kong stocks fell 5.09%, outperforming the Hang Seng Index of 6.17pp, and Hang Seng healthcare fell 10.11%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 28.64%, underperforming the Hang Seng Index by 14.77pp, and Hang Seng health care has fallen by 39.13%.
Progress of key innovative drugs in China
In March, four new drugs were approved for marketing in China. This week, three drugs were approved for listing in China, and three innovative drugs were approved for new indications. Nmpa approves AstraZeneca’s ineblizumab for optic neuromyelitis and optic neuromyelitis spectrum diseases. Baxter medical’s phosphorus / sodium bicarbonate hemofiltration replacement fluid was approved by nmpa as a replacement fluid for the treatment of acute renal injury during continuous renal replacement therapy (CRRT). SIPI’s epavamab was approved by nmpa for primary hemophagocytic lymphohistiocytosis (HLH). Bayer’s rivaroxaban tablet has been approved as a new indication for the treatment of venous thromboembolism (VTE) in children and adolescents and the prevention of VTE recurrence. Cornerstone pharmaceutical’s pratinib has been approved for a new indication, RET mutant medullary thyroid cancer (MTC). Baiji Shenzhou tirelizumab injection has been approved as a new indication for previously treated locally advanced unresectable or metastatic highly microsatellite unstable (MSI-H) or mismatch repair deficient (dmmr) solid tumors.
Progress of overseas key innovative drugs
In March, no new drug was approved by FDA. No new drugs have been approved this week.
This week’s small topic – research and development progress of CD47 target
There are 96 CD47 inhibitors under development in the world, including 3 in phase III, 1 in phase II / III, 2 in phase II, 8 in phase I / II, 19 in phase I and 5 in inds. There are 22 in research in China, including 1 phase III clinical (Xinda Biology), 2 phase II clinical, 3 phase I / II clinical, 11 phase I clinical and 5 inds. Among these CD47 projects, there are 33 double antibody projects, the vast majority of which are combined with CD47 and PD1 / 1pdl1 to form double antibodies. The fastest progress is the anti-CD47 / PD1 bispecific antibody of Hansi biology, which is in clinical phase II.
Progress of global key innovative drug transactions this week
This week, there were 6 key transactions in the world, and 2 key transactions with disclosed amount, involving companies including Voyager therapeutics and Novartis, bridge biotherapeutics and cellionbiomed.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
